The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC).
Rana R. McKay
No relevant relationships to disclose
Kathryn P. Gray
No relevant relationships to disclose
Julia H. Hayes
No relevant relationships to disclose
Glenn J. Bubley
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Philip W. Kantoff
No relevant relationships to disclose
Mary-Ellen Taplin
No relevant relationships to disclose